Back to Forecasting
RVMD Forecast Markets
Revolution Medicines, Inc.
7
Active Markets
25%
Avg Probability
All Markets
7 markets
Will RASolute 302 report a statistically significant improvement in overall survival by September 2026?
40%
Likely No
94% agreement
Sep 30, 2026
IG: 1.00
Will RVMD's FY2026 GAAP operating expenses exceed the high end of $1.7B guidance?
38%
Likely No
92% agreement
Mar 15, 2027
IG: 0.64
Will the FDA accept an NDA/BLA filing from RVMD for daraxonrasib by December 31, 2026?
25%
Likely No
94% agreement
Dec 31, 2026
IG: 0.64
Will a competitor receive FDA approval for a new RAS-targeted therapy in PDAC by December 31, 2026?
7%
Likely No
96% agreement
Dec 31, 2026
IG: 0.48
Will RVMD's cash and investments (excluding Royalty Pharma draws) fall below $1.0B by June 30, 2026?
10%
Likely No
96% agreement
Aug 15, 2026
IG: 0.48
Will RVMD draw more than $500M from the Royalty Pharma facility by December 31, 2026?
30%
Likely No
92% agreement
Mar 15, 2027
IG: 0.48
Will RVMD report that RASolve 301 (NSCLC Phase III) has completed enrollment by December 31, 2026?
28%
Likely No
92% agreement
Dec 31, 2026
IG: 0.48
Resolution Timeline
Aug 15, 2026
Will RVMD's cash and investments (excluding Royalty Pharma draws) fall below $1.0B by June 30, 2026?Prediction: 10%
Sep 30, 2026
Will RASolute 302 report a statistically significant improvement in overall survival by September 2026?Prediction: 40%
Dec 31, 2026
Will the FDA accept an NDA/BLA filing from RVMD for daraxonrasib by December 31, 2026?Prediction: 25%
Dec 31, 2026
Will a competitor receive FDA approval for a new RAS-targeted therapy in PDAC by December 31, 2026?Prediction: 7%
Dec 31, 2026
Will RVMD report that RASolve 301 (NSCLC Phase III) has completed enrollment by December 31, 2026?Prediction: 28%
Mar 15, 2027
Will RVMD's FY2026 GAAP operating expenses exceed the high end of $1.7B guidance?Prediction: 38%
Mar 15, 2027
Will RVMD draw more than $500M from the Royalty Pharma facility by December 31, 2026?Prediction: 30%